Mechanistic insights to the evolution of hormone-dependent tumors with deregulated PI3K signaling were first provided by Carver et al., who demonstrated that inhibition of AR activates AKT signaling by reducing levels of the AKT phosphatase PHLPP in prostate cancer cells [14]. The gene discussed is AKT1; the disease is prostate cancer.